Linsheng Cai
Overview
Explore the profile of Linsheng Cai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
58
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ke Q, He J, Cai L, Lei X, Huang X, Li L, et al.
Sci Rep
. 2024 Jun;
14(1):14848.
PMID: 38937539
This study aimed to assess the safety and efficacy of interventional embolization in cirrhotic patients with refractory hepatic encephalopathy (HE) associated with large spontaneous portosystemic shunts (SPSS). Inverse probability of...
2.
Hu E, Yang T, Cai L, Ouyang J, Wang F, Li Z, et al.
J Proteome Res
. 2024 Feb;
23(3):1062-1074.
PMID: 38373391
Hepatocellular carcinoma (HCC) is susceptible to early recurrence, but it lacks effective predictive biomarkers. In this study, we retrospectively selected 179 individuals as a discovery cohort (126 HCC patients and...
3.
Xing X, Cai L, Ouyang J, Wang F, Li Z, Liu M, et al.
Nat Commun
. 2023 Dec;
14(1):8392.
PMID: 38110372
Early diagnosis of hepatocellular carcinoma (HCC) lacks highly sensitive and specific protein biomarkers. Here, we describe a staged mass spectrometry (MS)-based discovery-verification-validation proteomics workflow to explore serum proteomic biomarkers for...
4.
Xing X, Hu E, Ouyang J, Zhong X, Wang F, Liu K, et al.
Cell Rep Med
. 2023 Dec;
4(12):101315.
PMID: 38091986
Patients with hepatocellular carcinoma (HCC) at the same clinical stage can have extremely different prognoses, and molecular subtyping provides an opportunity for individualized precision treatment. In this study, genomic, transcriptomic,...
5.
Chen H, Li Z, Qiu L, Dong X, Chen G, Shi Y, et al.
J Immunother Cancer
. 2022 Sep;
10(9).
PMID: 36113894
Background: Personalized neoantigen vaccine could induce a robust antitumor immune response in multiple cancers, whose efficacy could be further enhanced by combining with programmed cell death 1 blockade (α-PD-1). However,...
6.
Lin X, Wang X, Li J, Cai L, Liao F, Wu M, et al.
Nanoscale
. 2021 Jan;
13(3):1745-1758.
PMID: 33432957
Recently, photothermal therapy (PTT) in the second near-infrared (NIR-II) biowindow has emerged as a promising treatment modality; however, its therapeutic outcomes are still limited by heterogeneous heat distribution and insufficient...